TNFRSF8 and B-cell non-Hodgkin lymphoma: Similar to the CD19 CAR T therapy in leukemia and B cell lymphoma, CD30 is highly expressed in many kinds of PTCLs, and they are a potential target for PTCL CAR T therapy.